Featured News
461Wire StoriesSmartsheet Invests in Australia-based Data Hosting to Better Serve Global Customer Base
The enterprise work management leader’s newest regional deployment will provide customers the ability to host their data onshore in Australia, continuing to...
- 432Wire Stories
Fabrinet to Announce First Quarter Fiscal Year 2024 Financial Results on November 6, 2023
BANGKOK–(BUSINESS WIRE)–Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment...
- 373Wire Stories
Gold Resource Corporation Announces Q3 2023 Conference Call
DENVER–(BUSINESS WIRE)–Gold Resource Corporation (NYSE American: GORO) (the “Companyâ€) will host a conference call Friday, November 3, 2023 at 10:00 a.m. Eastern...
- 517Wire Stories
Polaris and OrionVM Partner to Next-Gen Cloud Transform Queensland ICT Market
OrionVM’s MicroPoP Technology Enables Leading Australian Data Centre to Uniquely Underpin Cloud Workloads, Including Enterprise Cloud, AI and Storage Solutions SYDNEY &...
- 417Wire Stories
New Chinese Restrictions on Supply of Natural Graphite Will Negatively Impact Batteries Used in EV Market
Westwater Resources Offers Domestic Alternatives CENTENNIAL, Colo.–(BUSINESS WIRE)–Westwater Resources, Inc. (NYSE: American: WWR), an energy technology and battery-grade natural graphite company (“Westwater...
- 494Wire Stories
Nanban Ventures Sends Letter Highlighting Steps Being Taken to Protect Investors
DALLAS–(BUSINESS WIRE)–Nanban Ventures LLC (“Nanban Venturesâ€), a Dallas-based venture capital firm investing in startups and other private companies that are committed to...
- 513Wire Stories
Avistone Announces Phase II Results for Vebreltinib, a c-Met Tyrosine Kinase Inhibitor (TKI) at the European Society for Clinical Oncology (ESMO) Congress
BEIJING–(BUSINESS WIRE)–Avistone Biotechnology Co., Ltd. (“Avistone†or “the Companyâ€), a clinical-stage biotechnology company focused on precision oncology therapeutics, announced preliminary results of...
- 571Wire Stories
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Daiichi Sankyo and AstraZeneca’s ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the...
- 669Wire Stories
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37%...
- 751Wire Stories
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median PFS benefit,...
- 428Wire Stories
athenahealth’s Annual ‘September is for Service’ Program Supports 50 Nonprofit Organizations Worldwide
Month-long campaign delivers more than $100,000 to nonprofit partners, with record employee participation BOSTON–(BUSINESS WIRE)–athenahealth, Inc., a leading provider of network-enabled software...
